Brokerages Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $5.00

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) have been given a consensus recommendation of “Hold” by the five brokerages that are covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $3.33.

Several analysts have recently commented on the company. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday. HC Wainwright reissued a “neutral” rating and issued a $1.00 price target (down from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday. StockNews.com cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $5.00 price objective (down from $13.00) on shares of Syros Pharmaceuticals in a report on Tuesday, August 13th.

Insider Buying and Selling

In related news, CFO Jason Haas purchased 35,363 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was bought at an average cost of $1.55 per share, with a total value of $54,812.65. Following the completion of the acquisition, the chief financial officer now directly owns 59,915 shares in the company, valued at $92,868.25. The trade was a 144.03 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Conley Chee purchased 50,000 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was bought at an average cost of $1.51 per share, with a total value of $75,500.00. Following the completion of the acquisition, the chief executive officer now owns 72,504 shares of the company’s stock, valued at approximately $109,481.04. The trade was a 222.18 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 130,707 shares of company stock valued at $206,491. 12.26% of the stock is owned by insiders.

Hedge Funds Weigh In On Syros Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. GSA Capital Partners LLP purchased a new stake in shares of Syros Pharmaceuticals in the third quarter valued at $34,000. Virtu Financial LLC purchased a new stake in Syros Pharmaceuticals during the first quarter valued at about $64,000. Acadian Asset Management LLC purchased a new stake in Syros Pharmaceuticals during the first quarter valued at about $91,000. Certuity LLC purchased a new stake in Syros Pharmaceuticals during the second quarter valued at about $109,000. Finally, Kennedy Capital Management LLC purchased a new stake in Syros Pharmaceuticals during the first quarter valued at about $2,166,000. 91.47% of the stock is owned by institutional investors and hedge funds.

Syros Pharmaceuticals Trading Down 5.7 %

Shares of SYRS stock opened at $0.26 on Wednesday. The business’s 50 day moving average is $2.02 and its two-hundred day moving average is $3.79. Syros Pharmaceuticals has a twelve month low of $0.25 and a twelve month high of $8.17. The company has a market capitalization of $6.96 million, a P/E ratio of -0.09 and a beta of 1.59. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 1.97.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same period last year, the firm earned ($1.35) earnings per share. Equities analysts forecast that Syros Pharmaceuticals will post -2.99 EPS for the current year.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.